Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California, San Diego Moores Cancer Center
La Jolla, California, United States
- University of Chicago Medical Center
Chicago, Illinois, United States
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
- Lifespan Comprehensve Cancer Center
Providence, Rhode Island, United States
- University of Utah, Huntsman Cancer Center
Salt Lake City, Utah, United States
- Unviersity of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 26 Oct 2017
- Primary completion
- 30 Nov 2021
- Completion
- 28 Dec 2026
- Last update posted
- 12 Aug 2026
- Registered enrollment
- 85
- Registry id
- NCT03203473
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.